Dishman raises ECB limit to CHF 200m for refinancing

Board clears FY26 audited results

Dishman Carbogen Amcis Limited said its Board of Directors approved the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The approvals were taken at the board meeting held on May 19, 2026. The update also included several corporate actions linked to funding and statutory compliance. Alongside the financials, the company disclosed changes to its external commercial borrowing (ECB) plan. The board’s decisions point to a continued focus on refinancing and reworking the group’s debt profile. The company indicated that some items will require shareholder approval. It also said related approvals will be pursued through a shareholder meeting.

Audit report and statutory auditor re-appointment

The statutory audit report for the audited results was issued by M/s T R Chadha & Co. LLP, Chartered Accountants. The report carried an unmodified opinion, as disclosed by the company. The board also recommended re-appointing M/s T R Chadha & Co. LLP as Statutory Auditors for a second term. The proposed tenure is five consecutive years. This re-appointment is subject to shareholder approval at the upcoming Annual General Meeting (AGM). Such re-appointments are typically aligned with Companies Act requirements and shareholder voting. The company has not disclosed any change in auditor or any qualifications in the audit report for the period.

ECB plan revised: limit raised to CHF 200 million

A key decision from the meeting was to revise the size of planned ECB fundraising. The board approved raising ECB up to CHF 200 million from promoter group company Aamanya AG. This revises the earlier proposed limit of CHF 135 million. The company said the ECB is intended to refinance existing debt. The loan is described as unsecured. The interest rate is SARON + 400 basis points, currently stated as 4% per annum. The tenor is 10 years.

Use of proceeds: refinancing, working capital, capex

Dishman Carbogen Amcis said the ECB proceeds will be used to refinance existing rupee debt. It also stated that funds may be used for working capital and capital expenditure requirements. The company added that the funds can be used for other permitted purposes. The stated end-use indicates a refinancing-driven transaction, with flexibility for operational funding within permitted ECB frameworks. The company did not provide a breakup of the refinancing quantum versus other uses. It also did not disclose any hedging policy or currency risk management details in the update. The lender being a promoter group entity is a central feature of the proposed structure.

Borrowing limits raised to ₹4,000 crore, pending approval

Following the ECB approval, the board also raised the overall borrowing ceiling under Section 180(1)(c) of the Companies Act, 2013. The borrowing limits were increased from ₹1,700 crore to ₹4,000 crore. The company clarified that this increase is subject to shareholder approval. Dishman Carbogen Amcis said it will seek consent for both the ECB and the higher borrowing limits through an Extra-Ordinary General Meeting (EGM). The EGM date will be communicated later. The combination of a higher ECB limit and a higher overall borrowing cap signals that the company is keeping headroom for debt actions beyond the immediate refinancing.

Key terms of the proposed ECB

The company also disclosed a snapshot of the proposed ECB terms. The loan size is CHF 200 million, which it approximated at ₹2,452 crore. Pricing is linked to SARON, which is a Swiss reference rate, plus a 400 bps spread. The loan is unsecured and has a long maturity profile of 10 years. The ECB structure and tenor can influence the company’s debt servicing profile compared with shorter-duration domestic borrowings. However, the company has not disclosed comparative interest costs for the debt that is planned to be refinanced.

Subsidiary update: Shanghai facility clears NMPA GMP inspection

Separately, Dishman Carbogen Amcis disclosed a regulatory update relating to its China operations. Its wholly-owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., underwent an unannounced Good Manufacturing Practice (GMP) inspection by China’s National Medical Products Administration (NMPA). The inspection took place at the Shanghai facility on April 14, 2026. The company said the inspection concluded with no observations identified. It added that no issues requiring formal explanation were identified, while recommendations were provided to support continuous improvement. The development was disclosed to stock exchanges on May 5, 2026 under Regulation 30 of SEBI (LODR) Regulations, 2015.

Recent funding and compliance trail in FY26

The company’s recent disclosures show multiple debt-related actions over the past few quarters. Dishman Carbogen Amcis completed allotment of 5,000 non-convertible debentures (NCDs) worth ₹50 crore on January 20, 2026, with each debenture having a face value of ₹1 lakh and issued at par through private placement. It had earlier approved an NCD issuance of up to ₹50 crore on December 27, 2025 with a 10% annual coupon rate and quarterly interest payments, and indicated the debentures would be secured by property and corporate guarantees. Another update in the provided disclosures refers to a board approval for a ₹150 crore NCD issuance at a 10% coupon (dated March 18, 2026). On the compliance side, the company submitted a confirmation certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, with the certificate issued by its RTA, MUFG Intime India Private Limited.

Market impact: what the decisions change

The immediate market relevance of the announcement lies in the shift in refinancing scale and the additional headroom for borrowings. Raising the ECB limit from CHF 135 million to CHF 200 million increases the potential size of the refinancing transaction. Increasing the overall borrowing limits to ₹4,000 crore from ₹1,700 crore also signals that the company wants flexibility to undertake funding actions, subject to shareholder consent. The stated interest rate for the ECB is SARON + 400 bps, currently indicated as 4% per annum, and the long 10-year tenor could alter the maturity mix of borrowings if executed. At the same time, the company has highlighted operational compliance strength through the Shanghai facility’s GMP inspection outcome, which is relevant for regulated manufacturing operations.

Why this matters: refinancing focus and regulatory execution

The board decisions highlight two parallel priorities: funding structure and execution readiness. On the funding side, the proposal explicitly targets refinancing of existing rupee debt while allowing use for working capital and capex within permitted purposes. The plan relies on promoter group funding via Aamanya AG, and the company is seeking formal shareholder approvals through an EGM. On operations, the NMPA inspection outcome is a disclosure that supports the subsidiary’s regulatory standing, with the company stating the inspection ended with no observations. Together, these updates provide investors with two concrete signals: a refinancing plan with disclosed pricing and tenor, and a recent regulatory inspection outcome for a key overseas facility.

What to watch next

Dishman Carbogen Amcis has said the EGM date will be communicated later, and shareholder approvals are required for both the ECB and the enhanced borrowing limits. The re-appointment of statutory auditors is also subject to shareholder approval at the AGM. Further updates could include EGM scheduling, detailed borrowing documentation, and any further disclosures on execution timelines for the ECB refinancing. Any subsequent exchange filings related to the EGM notice and explanatory statement will be important for additional specifics.

Conclusion

Dishman Carbogen Amcis’ board has approved FY26 audited results and moved to expand its refinancing room by raising the ECB limit to CHF 200 million while increasing overall borrowing limits to ₹4,000 crore, both pending shareholder approval. The company has also disclosed that its Shanghai subsidiary cleared an unannounced NMPA GMP inspection with no observations. The next confirmed step is shareholder voting through an EGM for the ECB and borrowing cap, with the meeting date to be announced by the company.